Abingworth has promoted Ken Haas and Vin Miles to partners. They are both based in the US where they source and manage deals including early stage and late stage venture capital, venture growth and public market investments as well as VIPEs (venture investments in public equities).
PRESS RELEASE
Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the promotions of Ken Haas and Vin Miles to Partners. They are both based in the US where they source and manage deals including early-stage and late-stage venture capital, venture growth and public market investments as well as VIPEs (Venture Investments in Public Equities).
Ken Haas has spent 25 years in the management of both early-stage and public high technology and biotechnology companies. As part of the Abingworth team, Ken has led several investments including Clovis Oncology, Gynesonics and Intellikine. Before joining Abingworth, he was part of the founding management team at IntelliGenetics, one of the world’s first bioinformatics companies and was CEO of IntelliCorp, a publicly-traded enterprise software company. Ken joined Abingworth in 2004 and is based in our Menlo Park, CA office.
Vin Miles has more than 30 years of management experience in the biotech industry. He is currently on the boards of Chiasma, Dicerna, Hydra BioSciences and Magellan Bioscience. Before joining Abingworth in 2007, he was Senior Vice President, Business Development, of the Abingworth portfolio company, Alnylam Pharmaceuticals. Previously, Vin was at Millennium Pharmaceuticals, where he held VP positions in business development, strategic planning and corporate communications. Vin is based in our Boston, MA office.
“We are pleased to announce the promotions of Ken and Vin,” said Stephen Bunting, Managing Partner. “They both have extensive operating experience and have made significant contributions to our portfolio companies from our Menlo Park and Boston offices.”
Notes for Editors
About Abingworth
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. Founded in 1973, Abingworth has a lengthy track record of backing market leading companies. Abingworth has a specialist team of 26 professionals with a broad range of skill sets and access to an extensive network of industry contacts. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.
To date, Abingworth has raised 15 funds including ten venture funds dedicated to investment in life sciences and healthcare. Successful investments have included Ablynx, Algeta, Alkermes, Alnylam, Amarin, Avila Therapeutics, Chiasma, Clovis Oncology, Fovea, Geltex, Genetic Therapy, Gilead, IDEC Pharmaceuticals, Intellikine, Novexel, Pharmion, PowderMed and Solexa.
